Working… Menu

Gender Differences in the Metabolic Effects of Uric Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03076684
Recruitment Status : Withdrawn (Preliminary data collected and diets developed. Funding has ended and data used to support a larger application to test the hypothesis.)
First Posted : March 10, 2017
Last Update Posted : April 17, 2019
Information provided by (Responsible Party):
Elizabeth Parks, University of Missouri-Columbia

Brief Summary:
Increased stiffening of the heart and blood vessels is a predictor of heart disease. Stiffening has been found to be greater in women than men, which puts women with poor blood sugar control at a greater risk for heart disease than men. In women only, a molecule in the blood called uric acid can be elevated due to diets high in fructose consumption and it is thought to be a cause of heart and vessel stiffening. From previous research, we have found that restricting fructose in the diet lowers uric acid more in women than men. There is also a drug that can be used to lower uric acid. These findings suggest a potential approach to decrease vessel and heart stiffness in women. The present study will investigate fructose restriction in the diet and drug treatment to lower uric acid in the blood and its effects on heart disease risk in women compared to men.

Condition or disease Intervention/treatment Phase
Hyperuricemia Other: low-fructose diet Drug: Allopurinol Early Phase 1

Detailed Description:

This project will use treatments from 4-8 months to lower uric acid in men and women. This study has three parts and each subject will participate in only one part. Tests that will be performed before and after treatment include measurements of body weight, blood pressure, blood vessel stiffness, heart stiffness, and blood lipids and glucose.

Part 1: Dietary treatment The overall goal of part 1 is to remove fructose and simple sugars from the diets of women and men at risk for future heart disease. Dietary fructose will be replaced with starchy foods to keep the research subjects' body weights stable. Subjects will be treated for 4 months and measurements of vascular and heart stiffness will be made before, during, and after treatment.

Part 2: Drug treatment The overall goal of part 2 is to treat women and men with mild elevations in blood uric acid for 8 months. The treatment will be allopurinol administration, ramping up the dose over a 2 month period to achieve a uric acid concentration of 6 mg/dL. Measurements of vascular and heart stiffness will be made before, during, and after.

Part 3: Control, no treatment These individuals will undergo the same baseline and follow-up tests as the other two parts but have no treatments.

Tests that will be completed before and after

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: There are three arms of this study: a diet-treated group, a drug-treated group and a control group.
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Gender Differences in the Metabolic Effects of Uric Acid
Actual Study Start Date : March 3, 2017
Estimated Primary Completion Date : December 2018
Actual Study Completion Date : March 13, 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: low-fructose diet
Intervention: low-fructose Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
Other: low-fructose diet
Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.

Experimental: allopurinol treatment
Subjects participating in the allopurinol treatment arm will begin with an initial dose of drug of 100 mg/d p.o. daily for 2 wks. The dose is then slowly increased over the next 8 wks to achieve a serum uric acid concentration of 6 mg/dL (maximum allopurinol dose is 800 mg/d). Once uric acid reaches 6 mg/dL, the subject stays on this dose and is seen for the interim visit (4 months), at which time all procedures are repeated. After this, drug treatment continues for another 4 months and the subject returns for the final visit at 8 months. The same procedures performed at baseline are repeated at this time. The dose of allopurinol will be taken the morning of the final visit.
Drug: Allopurinol
Subjects in the drug arm will take the drug allopurinol daily.

No Intervention: control arm
After completion of the baseline visit (procedures described above), subjects participating in the control arm are not seen again until the 4-month time point, when the same procedures performed at baseline are repeated, except for the MRI. Following this, they are seen again at 8-months, when all baseline procedures are repeated. Cardiac MRI and labeled water consumption occur at the baseline and final visits.

Primary Outcome Measures :
  1. vessel stiffness [ Time Frame: Change from baseline at 4 months ]
    blood vessel stiffness is measured non-invasively with pulse wave velocity

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   40 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  1. Men and women with characteristics of the metabolic syndrome.
  2. 40-70 years of age
  3. Overweight/obese subjects with BMI 25.1 - 40.0 kg/m2
  4. Pre-diabetes defined as fasting glucose 100 - 125 mg/dL or 2h glucose 140 - 200 mg/dL
  5. Habitual diets containing ≥ 13.0% of energy from added sugars
  6. Serum uric acid ≥ 7.0 mg/dL for men and women

Exclusion Criteria:

  1. Renal dysfunction (defined by glomerular filtration rate [GFR] <60), abnormal thyroid function or liver disease
  2. Use of diuretics or azathioprine
  3. Diabetes defined as fasting glucose ≥ 125 mg/dL or HbA1c ≥ 7%
  4. Use of medications that interfere with lipid, protein, or carbohydrate metabolism, or occasional or regular tobacco use
  5. Habitual diets with low content of added sugars (<5% of total energy)
  6. History of gout , gouty arthritis, or uncontrolled hypertension
  7. Pregnant
  8. Vegetarian food restrictions (the diets consumed contain some meat, eggs and dairy)
  9. Alcohol intake: females > 70 g/wk, males >140 g/wk
  10. Inability to have an MRI

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03076684

Layout table for location information
United States, Missouri
University of Missouri
Columbia, Missouri, United States, 65212
Sponsors and Collaborators
University of Missouri-Columbia
Layout table for investigator information
Principal Investigator: Elizabeth Parks, PhD University of Missouri-Columbia

Layout table for additonal information
Responsible Party: Elizabeth Parks, Professsor, University of Missouri-Columbia Identifier: NCT03076684     History of Changes
Other Study ID Numbers: 2007093
First Posted: March 10, 2017    Key Record Dates
Last Update Posted: April 17, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pathologic Processes
Uric Acid
Molecular Mechanisms of Pharmacological Action
Enzyme Inhibitors
Gout Suppressants
Antirheumatic Agents
Free Radical Scavengers
Protective Agents
Physiological Effects of Drugs